CHMP-CAT - D80-210 Overview to final EPAR - Rev 07.25 Revamp

Opinion on medicine for use outside EU: Fexinidazole Winthrop, fexinidazole, Trypanosomiasis, African, 15/11/2018 Positive opinion

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Omnitrope, somatropin, Date of authorisation: 12/04/2006, Revision: 23, Status: Authorised

Quetiapine

Human medicines European public assessment report (EPAR): Emtricitabine / Tenofovir alafenamide Viatris, emtricitabine,tenofovir alafenamide, Date of authorisation: 18/07/2025, Status: Authorised

Human medicines European public assessment report (EPAR): mResvia, single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation, Date of authorisation: 22/08/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Livtencity, maribavir, Date of authorisation: 09/11/2022, Revision: 6, Status: Authorised

PSUSA/00002013/202412